TY - JOUR
T1 - L1CAM expression in endometrial carcinomas: An ENITEC collaboration study
AU - Van Der Putten, Louis J.M.
AU - Visser, Nicole C.M.
AU - Van De Vijver, Koen
AU - Santacana, Maria
AU - Bronsert, Peter
AU - Bulten, Johan
AU - Hirschfeld, Marc
AU - Colas, Eva
AU - Gil-Moreno, Antonio
AU - Garcia, Angel
AU - Mancebo, Gemma
AU - Alameda, Fransesc
AU - Trovik, Jone
AU - Kopperud, Reidun K.
AU - Huvila, Jutta
AU - Schrauwen, Stefanie
AU - Koskas, Martin
AU - Walker, Francine
AU - Weinberger, Vit
AU - Minar, Lubos
AU - Jandakova, Eva
AU - Snijders, Marc P.L.M.
AU - Van Den Berg-Van Erp, Saskia
AU - Matias-Guiu, Xavier
AU - Salvesen, Helga B.
AU - Amant, Frederic
AU - Massuger, Leon F.A.G.
AU - Pijnenborg, Johanna M.A.
PY - 2016/9/6
Y1 - 2016/9/6
N2 - © 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
AB - © 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
KW - L1CAM
KW - endometrial cancer
KW - endometrioid
KW - immunohistochemistry
KW - non-endometrioid
U2 - 10.1038/bjc.2016.235
DO - 10.1038/bjc.2016.235
M3 - Article
SN - 0007-0920
VL - 115
SP - 716
EP - 724
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 6
ER -
